End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
5-day change
1st Jan Change
29,900
KRW
+2.57%
-2.76%
-25.71%
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.
October 04, 2023 at 12:51 pm IST
From July 1, 2023 to September 30, 2023, the company has repurchased 20,242 shares, representing 0.1% for KRW 446.17 million. With this, the company has completed the repurchase of 73,961 shares, representing 0.36% for KRW 891.08 million under the buyback announced on April 5, 2023.
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal
22/12
MT
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.
04/23/04
CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.
04/23/04
CI
Peptron, Inc.'s Equity Buyback announced on April 5, 2023, has expired with 73,961 shares, representing 0.36% for KRW 891.08 million.
04/23/04
CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.
07/23/07
CI
Peptron, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.
05/23/05
CI
Peptron, Inc. authorizes a Buyback Plan.
05/23/05
CI
Peptron, Inc. Establishes Bioequivalence of PT105
28/22/28
CI
Invex Therapeutics Ltd Announces the Signing of a Long Term Collaboration and Manufacturing Agreement with Peptron, Inc
27/21/27
CI
Qilu Pharmaceutical and Peptron Sign License Agreement for Anti-MUC1 ADC
16/21/16
CI
Peptron, Inc. Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model
16/18/16
CI
Peptron, Inc. announced that it has received $24 million in funding
23/18/23
CI
Peptron, Inc. announced that it has received KRW 25.5 billion in funding from Industrial Bank of Korea
31/18/31
CI
Peptron, Inc. announced that it expects to receive KRW 25.5 billion in funding from Industrial Bank of Korea
29/18/29
CI
Peptron, Inc. announced that it has received funding from E&Investment,Inc.
25/16/25
CI
Peptron, Inc. announced that it has received KRW 2 billion in funding from UNO & COMPANY Ltd.
25/16/25
CI
Peptron, Inc. announced that it expects to receive KRW 2 billion in funding from UNO & COMPANY Ltd.
20/16/20
CI
Peptron, Inc.(KOSDAQ:A087010) added to Russell Global Index
01/15/01
CI
Peptron, Inc.(KOSDAQ:A087010) added to S&P Global BMI Index
21/15/21
CI
Peptron, Inc. has completed an IPO in the amount of KRW 13.04 billion.
17/15/17
CI
Peptron, Inc. has filed an IPO.
04/14/04
CI
UNO&COMPANY Ltd. acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion.
10/14/10
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-25.71% 46Cr +7.52% 11TCr +11.38% 11TCr +0.90% 2.23TCr -12.64% 2.22TCr -4.41% 1.94TCr -37.85% 1.79TCr -8.58% 1.72TCr +7.77% 1.43TCr +37.41% 1.25TCr
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**